相关实验视频
Updated: Jul 4, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
关于在青少年皮肤肌肉炎中使用 janus 激酶抑制剂的疗效和安全性的最新信息
1National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Expert review of clinical immunology
|February 1, 2024
概括
简氏激酶抑制剂 (jakinibs) 显示出治疗青少年皮肤肌炎 (JDM),一种罕见的自身免疫性疾病的前景. 大多数不耐药的JDM患者对雅基尼布治疗有反应,这表明了潜在的新治疗途径.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 青少年皮肤肌炎 (JDM) 是一种罕见的自身免疫性疾病,其特征是肌肉疲软和皮肤皮疹.
- 标准疗法往往导致慢性或复发性疾病过程,突出显示了对新型治疗的需求.
- 干扰素 (IFN) 途径与JDM病原发生有关,这表明有针对性的疗法是合理的.
研究的目的:
- 审查关于在患有JDM的患者中使用Janus激酶抑制剂 (jakinibs) 的现有文献.
- 总结JDM中雅基尼布治疗研究中的疗效,安全性和患者特征.
- 评估雅基尼布作为针对JDM的向治疗的潜力.
主要方法:
- 涉及使用雅基尼布斯治疗的JDM患者的研究文献综述.
- 对雅基尼布暴露,疗效,疾病特征和安全参数数据的分析.
- 综合追溯数据以评估治疗结果.
主要成果:
- 大多数不耐药的JDM患者对雅基尼布治疗产生了积极反应.
- 患者表现出不同的疾病特征,治疗剂量和同时服用的药物.
- 数据主要来自回顾性研究,表明需要进一步调查.
结论:
- 雅努斯激酶抑制剂 (jakinibs) 代表了对JDM的一个有前途的治疗选择.
- 进一步的前性,受控研究对于优化剂量,患者选择,生物标志物识别和在JDM中监测杰基尼布的安全性至关重要.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Antiasthma Drugs: Leukotriene Modifiers
300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
300

